Transcutaneous versus Total Serum Bilirubin Measurements in Preterm Infants

Thivia Jegathesan\textsuperscript{a, b}  Douglas M. Campbell\textsuperscript{b, c}  Joel G. Ray\textsuperscript{a, d, e}  Vibhuti Shah\textsuperscript{c, e, f}  Howard Berger\textsuperscript{d, e}  Robin Z. Hayeems\textsuperscript{g}  Michael Sgro\textsuperscript{a, b, c}  for the NeoHBC

\textsuperscript{a}Institute of Medical Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; \textsuperscript{b}Department of Pediatrics, and Li Ka Shing Knowledge Institute, Unity Health Toronto at St. Michael’s Hospital, Toronto, ON, Canada; \textsuperscript{c}Department of Pediatrics, Division of Neonatology, University of Toronto, Toronto, ON, Canada; \textsuperscript{d}Department of Obstetrics and Gynecology, and Li Ka Shing Knowledge Institute, Unity Health Toronto at St. Michael’s Hospital, Toronto, ON, Canada; \textsuperscript{e}Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada; \textsuperscript{f}Department of Paediatrics, Sinai Health, Toronto, ON, Canada; \textsuperscript{g}Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, ON, Canada

Keywords
Hyperbilirubinemia · Newborn screening · Jaundice · Neonatal pain · Blood tests

Abstract
Introduction: Transcutaneous bilirubin (TcB) measurement offers a noninvasive approach for bilirubin screening; however, its accuracy in preterm infants is unclear. This study determined the agreement between TcB and total serum bilirubin (TSB) among preterm infants. Methods: A multisite prospective cohort study was conducted at 3 NICUs in Ontario, Canada, September 2016 to June 2018. Among 296 preterm infants born at 24\textsuperscript{0/7} to 35\textsuperscript{6/7} weeks, 856 TcB levels were taken at the forehead, sternum, and before and after the initiation of phototherapy with TSB measurements. Bland-Altman plots and 95\% limits of agreement (LOA) expressed agreement between TcB and TSB. Results: The overall mean TcB-TSB difference was \(-24.5\text{ μmol/L} (95\% \text{ LOA} \text{−}103.3 \text{ to } 54.3)\) at the forehead and \(-24.4\text{ μmol/L} (95\% \text{ LOA} \text{−}112.9 \text{ to } 64.0)\) at the sternum. The mean TcB-TSB difference was \(-31.4\text{ μmol/L} (95\% \text{ LOA} \text{−}95.3 \text{ to } 32.4)\) among infants born 24–28 weeks, \(-25.5\text{ μmol/L} (95\% \text{ LOA} \text{−}102.7 \text{ to } 51.8)\) at 29–32 weeks, and \(-15.9\text{ μmol/L} (95\% \text{ LOA} \text{−}107.4 \text{ to } 75.6)\) at 33–35 weeks. Measures did not differ by maternal ethnicity. Conclusion: Among preterm infants, TcB may offer a noninvasive, immediate approach to screening for hyperbilirubinemia with more careful use in preterm infants born at <33 weeks’ gestation, as TcB approaches treatment thresholds. Its underestimation of TSB after the initiation of phototherapy warrants the use of TSB for clinical decision-making after the initiation of phototherapy.

Introduction
The decline in acute and chronic bilirubin encephalopathies in Canada and the USA can be attributed, in part, to the adoption of American Academy of Pediatrics’...
and Canadian Paediatric Society’s recommendations to perform routine total serum bilirubin (TSB) screening in infants born at >35 weeks’ gestation prior to hospital discharge [1–3] and among preterm infants born at 24–35 weeks’ gestation [4, 5].

Although obtaining TSB is the most common way to measure bilirubin levels in infants, blood sampling can be painful and a time-consuming procedure [6, 7]. Studies have also reported concerns about frequent TSB measurements, such as the increased risk of infection and anemia, particularly among extremely preterm infants [8, 9]. Furthermore, repeated procedural pain and stress have been documented in preterm infants [10].

In term and near-term infants, the use of noninvasive transcutaneous bilirubin (TcB) measurement has gained use in clinical practice, as it can reduce the frequency of TSB tests when TSB concentrations are <240 μmol/L (<14 mg/dL) [1, 2]. There is a conflicting body of research on the use of TcB in preterm infants ≤35 weeks’ gestation. Prior studies included small sample sizes, with conflicting data reporting the effects of phototherapy and anatomical site of measurement [11–13]. There are also limited data reporting the effects of ethnicity on TcB in preterm infants [13, 14]. In addition, few recent studies have stratified agreement between TcB and TSB by gestational age groups of prematurity among preterm infants, especially after the initiation of phototherapy [12].

The primary objective of this study was to evaluate the agreement (i.e., limits of agreement [LOA]) between TcB and TSB measurements among preterm infants born at 24<sup>0/7</sup> to 35<sup>6/7</sup> weeks’ gestation. We also assessed the agreement between TcB and TSB before and after the initiation of phototherapy, by anatomical site of measurement and the infant’s ethnicity.

**Materials and Methods**

A multisite prospective cohort study was completed in Ontario at St. Michael’s Hospital, Sinai Health, and Hamilton Health Sciences Centre from September 2016 to June 2018. Eligible participants were preterm infants born at 24<sup>0/7</sup> to 35<sup>6/7</sup> weeks’ gestation and admitted to participating sites. Excluded were those with a condition that could interfere with TcB measurements, such as hydrops fetalis, congenital malformation, diffuse cutaneous conditions, infection, or purpura.

The JM-105 TcB device (Drager Medical Systems Inc., Telford, Philadelphia) was used to measure TcB in each participating infant within 15 min of every TSB measurement. TSB samples were collected by venous or capillary blood sampling as per clinical decision and analyzed by spectrophotometry using Beckman Coulter’s AU680 automated analyzer (online suppl. Text 1; for all online suppl. material, see www.karger.com/doi/10.1159/000516648).

Participating sites were provided 2–3 TcB devices which were calibrated daily as per manufacturer’s instructions. As per hospital policy, with every medically indicated TSB measurement, a single TcB (average of 3 measurements) was concomitantly taken at both the forehead and sternum by nurses from time of parental consent up to 10 days, in the NICU. TcB sampling was repeated in each infant at every subsequently required TSB. Phototherapy was started as medically indicated based on TSB measurements. During phototherapy, phototherapy lights were turned off when TSB and TcB measurements were taken at each site. Nursing staff at all 3 sites were trained by the primary site investigator on how to perform TcB measurements as per procedures described above. Research assistants then collected the results directly from the meter and entered them on the data collection form.

Also recorded were infant age (in hours) at each TSB-TcB measurement and the time of initiation of phototherapy. Maternal and infant demographic data and clinical information were collected via standardized chart extraction.

**Data Analyses**

The primary study outcome was the agreement between TcB and TSB. Agreement was assessed among all infants (“overall”), before and after initiation of phototherapy, by anatomical site (forehead vs. sternum), and by infant ethnicity, determined by maternal self-identified ethnicity (Canadian Caucasian, Southeast Asian, South Asian, and African or Caribbean). To express the level of agreement between TcB and TSB measurements, Bland-Altman plots and Lin’s concordance correlation coefficient (CCC) were generated. Adapted Bland-Altman plots were weighted for multiple TcB and TSB measurements per infant and the 2 sites of TcB measurement (forehead and sternum), with 95% LOA [15, 16]. Agreement was assessed, overall, in all preterm infants and further stratified by gestational age (24–28, 29–32, and 33–35 weeks’ gestation at birth). Bland-Altman plots were also developed for TcB-TSB measurement differences before or after phototherapy, anatomical site of measurement (forehead vs. sternum), and infant ethnicity.

To assess the use of TcB as a potential screening test for hyperbilirubinemia, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive and negative likelihood ratios were calculated at clinically important TSB cut points as recommended by Maisels et al. [5] and which are widely used in North America. For preterm infants born at 24–28 weeks, the lack of TcB measurements prior to phototherapy prohibited any similar analysis, as described below. The recommended TSB cut points are 103–171 μmol/L in infants born at 29–32 weeks and 171–205 μmol/L in infants at 33–35 weeks [1, 5]. Accordingly, a rounded off cut point TSB >100 μmol/L was applied to infants born at 29–32 weeks’ gestation, and a rounded off cut point >170 μmol/L was used for those at 33–35 weeks. Receiver operating characteristic curves, and the respective area under the curves (AUC), were also calculated. Finally, TcB cut points were determined with at least 90% sensitivity to detect a TSB of >100 μmol/L at 29–32 weeks’ gestation and a TSB of >170 μmol/L at 33–35 weeks.

**Sample Size Calculation**

In one previous study, the mean TSB was 146 μmol/L, with a standard deviation of the average difference between TSB and TcB...
measurements of 30 µmol/L and negligible variation by gestational age or ethnicity [17]. With our a priori sample size calculation of a minimum of 271 infants, the current study sample of 296 infants was sufficient to detect a minimum TcB-TSB difference of 4 µmol/L, at a conventional 2-sided \( p \) value of 0.05 and a statistical power of 80%. Analyses were conducted using NCSS 12 and SPSS 26.

### Results

Out of 344 preterm infants born at 24\(^{0/7}\) and 35\(^{6/7}\) weeks, 296 preterm infants received at least 1 TcB measurement (online suppl. Fig. 1). The median gestational age at birth was 31.0 weeks (IQR 28.0–33.0) among an ethnically diverse group of mothers (Table 1). Each of the 296 infants received a mean (SD) of 7.0 (3.6) TSB measurements. There were 856 paired TcB and TSB measurements done at both the forehead and sternum, with a mean of 3.0 (1.9) paired measurements per infant performed at a median age of 105 h (IQR 68–151).

Among all 296 infants, the overall mean TcB-TSB difference was −24.5 µmol/L (to convert TSB to mg/dL divide by 17.1) (95% LOA −103.3 to 54.3) (Fig. 1a). There were 29 (3.4%) measures above the upper LOA and 73 (8.5%) below the lower LOA, with no visual evidence of any greater deviation at higher mean bilirubin concentrations (Fig. 1a). Furthermore, TcB underestimated TSB in 650 of all measures (75.9%) and overestimated TSB in 206 of all measures (24.1%) (Fig. 1a).

Table 1. Characteristics of the 296 preterm infants included in the study

| Characteristic                                      | Measurement                  |
|-----------------------------------------------------|------------------------------|
| Median (IQR) gestational age, weeks                 | 31.0 (28.0–33.0)             |
| Mean (SD) birth weight, g                            | 1,558.8 (612.8)              |
| Sex (female)                                        | 134 (45.3)                   |
| **Mode of delivery**                                |                              |
| Cesarean                                            | 180 (60.8)                   |
| Vaginal                                             | 101 (34.1)                   |
| Unknown                                             | 15 (5.1)                     |
| **Maternal ethnicity**                              |                              |
| Canadian Caucasian                                  | 110 (37.2)                   |
| Unknown                                             | 90 (30.4)                    |
| Southeast Asian                                     | 27 (9.1)                     |
| South Asian                                         | 26 (8.8)                     |
| African or Caribbean                                | 20 (6.7)                     |
| Hispanic                                            | 12 (4.1)                     |
| Middle Eastern                                      | 6 (2.0)                      |
| First Nations or Inuit                              | 5 (1.7)                      |
| Mean (SD) number of hours from birth to initiation of phototherapy | 42.9 (30.9) |
| TcB measurements among all infants, prior to initiation of phototherapy, \( N \) | 172                          |
| TcB measurements among all infants, after initiation of phototherapy, \( N \) | 684                          |
| TSB measurements >100 µmol/L prior to the initiation of phototherapy, n | 138                          |
| TSB measurements >170 µmol/L prior to the initiation of phototherapy, n | 34                           |

All data are shown as \( n \) (%) unless otherwise indicated. TcB, transcutaneous bilirubin; TSB, total serum bilirubin.

Among all newborns, the overall mean TcB-TSB difference at the combined forehead and sternum was much smaller prior to the initiation of phototherapy (1.6 µmol/L, 95% LOA −73.4 to 76.5) (Fig. 1b) than after (−31.1 µmol/L, 95% LOA −105.5 to 43.4) (Fig. 1c). TcB overestimated TSB in 99 (57.6%) measures prior to the
Fig. 1. Bland-Altman plots of paired TcB and TSB measurements among all 296 preterm infants at 24–35 weeks’ gestation, measured overall (a), prior to (b), and after (c) initiation of phototherapy. TcB, transcutaneous bilirubin; TSB, total serum bilirubin.

(Figure continued on next page.)
start of phototherapy and underestimated TSB in 577 (84.4%) measures after. The corresponding Lin’s CCC was 0.76 (95% CI: 0.69–0.81) prior to starting phototherapy and 0.64 (95% CI: 0.60–0.67) after.

**Sites of TcB Measurement**

The overall mean TcB-TSB difference at the forehead (−15.2 μmol/L, 95% LOA −86.8 to 56.3) was less pronounced than at the sternum (−24.4 μmol/L, 95% LOA −112.9 to 64.0) (Table 2). This was consistent after receipt of phototherapy and upon stratifying by gestational age at birth (Table 2). Lin’s CCC between TSB and TcB at the forehead was consistently higher than at the sternum (Table 2).

**TcB Measurement by Gestational Age Groups**

Regardless of phototherapy, 241 paired TcB-TSB measurements were obtained in 79 neonates born at 24–28 weeks, 381 paired measurements in 119 infants born at 29–32 weeks, and 234 paired measurements in 98 infants born at 33–35 weeks. At the forehead and sternal sites combined, the mean TcB-TSB difference was −31.1 μmol/L (95% LOA −105.5 to 43.4) at 24–28 weeks, −25.5 μmol/L (95% LOA −95.3 to 43.4) at 29–32 weeks, and −15.9 μmol/L (95% LOA −107.4 to 75.6) at 33–35 weeks. However, upon limiting to TcB at the forehead (where higher overall LOA were observed regardless of phototherapy), the mean TcB-TSB difference was less pronounced, especially among late-preterm infants (Fig. 2c). This was consistently seen when stratified by receipt of phototherapy and site of measurement (Table 2). TcB underestimated TSB in 216 (89.6%) of the measures done in infants born at 24–28 weeks, 302 (79.3%) of those at 29–32 weeks, and 132 (56.4%) of the measures in infants born at 33–35 weeks.

**Influence of Ethnicity on TcB**

The overall LOA between TSB and TcB (both prior to and after the initiation of phototherapy) were similar across the 4 main ethnic groups, including infants born to a mother of African or Caribbean ethnicity (online suppl. Fig. 2).

**Performance of TcB at Predefined TSB Levels**

Among infants born at 29–32 weeks’ gestation and at the recommended TSB cut point of >100 μmol/L, prior to phototherapy, forehead TcB had an AUC of 0.76 (95% CI: 0.59–0.87) (Fig. 3a; Table 3.). A forehead TcB cut point of...
85 μmol/L had a sensitivity of 92% (95% CI: 80–98), specificity 60% (95% CI: 32–84), PPV 88% (95% CI: 76–95), NPV 69% (95% CI: 38–91), and respective positive and negative likelihood ratios of 2.3 (95% CI: 1.2–4.3) and 0.14 (95% CI: 0.05–0.39) to detect the recommended TSB threshold of >100 μmol/L at 29–32 weeks’ gestation.

In preterm infants born at 33–35 weeks’ gestation and at the recommended TSB cut point of >170 μmol/L, forehead TcB had an AUC of 0.86 (95% CI: 0.76–0.92) (Fig. 3b; Table 3, ). A forehead TcB cut point of 156 μmol/L had a sensitivity of 90% (95% CI: 73–98), specificity 69% (95% CI: 57–80.0), PPV 55% (95% CI: 40–70), NPV 94% (95% CI: 83–99), and respective positive and negative likelihood ratios of 2.9 (95% CI: 2.0–4.2) and 0.15 (95% CI: 0.05–0.44) to detect the recommended TSB threshold of >170 μmol/L among infants born at 33–35 weeks.

Table 2. Agreement between measurement of TcB and TSB among all 296 preterm infants included in the study

| Group assessed                      | Site of measurement | Stratification variable (paired measurements, n) | Bland-Altman mean TcB-TSB difference (95% LOA), μmol/L | Lin’s concordance coefficient (95% CI) between TcB and TSB |
|-------------------------------------|---------------------|--------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------|
| All neonates, born at 24–35 weeks’ gestation | Forehead | Regardless of phototherapy (856) | −15.2 (−86.8 to 56.3) | −143.3, 109.3 | 0.68 (0.65–0.71) |
|                                     | Forehead | Prior to phototherapy (172) | 5.0 (−66.0 to 76.1) | −122.0, 109.3 | 0.74 (0.67–0.80) |
|                                     | Forehead | During or after phototherapy (684) | −24.2 (−91.5 to 43.2) | −143.3, 86.0 | 0.65 (0.62–0.69) |
|                                     | Sternum | Regardless of phototherapy (856) | −24.4 (−112.9 to 64.0) | −176.1, 113.3 | 0.58 (0.54–0.61) |
|                                     | Sternum | Prior to phototherapy (172) | 1.1 (−80.0 to 82.2) | −165.5, 113.3 | 0.68 (0.61–0.75) |
|                                     | Sternum | During or after phototherapy (684) | −35.4 (−119.7 to 48.9) | −176.1, 79.0 | 0.54 (0.50–0.58) |
| Neonates born at 24–28 weeks’ gestation | Forehead | During or after phototherapy (229) | −25.9 (−84.3 to 32.6) | −133.1, 86.0 | 0.49 (0.42–0.56) |
|                                     | Sternum | During or after phototherapy (229) | −40.2 (−106.5 to 26.1) | −176.1, 44.7 | 0.35 (0.29–0.42) |
| Neonates born at 29–32 weeks’ gestation | Forehead | Regardless of phototherapy (381) | −18.4 (−82.8 to 46.0) | −143.3, 108.3 | 0.54 (0.48–0.60) |
|                                     | Forehead | Prior to phototherapy (63) | −2.6 (−81.3 to 76.1) | −122.0, 108.3 | 0.60 (0.44–0.72) |
|                                     | Forehead | During or after phototherapy (318) | −21.8 (−82.8 to 39.2) | −143.3, 70.6 | 0.54 (0.47–0.59) |
|                                     | Sternum | Regardless of phototherapy (381) | −26.2 (−108.6 to 56.2) | −165.5, 96.3 | 0.45 (0.39–0.50) |
|                                     | Sternum | Prior to phototherapy (63) | −3.1 (−91.1 to 84.9) | −165.5, 96.3 | 0.52 (0.36–0.65) |
|                                     | Sternum | During or after phototherapy (318) | −32.2 (−111.8 to 47.4) | −150.0, 71.6 | 0.44 (0.38–0.49) |
| Neonates born at 33–35 weeks’ gestation | Forehead | Regardless of phototherapy (234) | −5.0 (−88.4 to 78.4) | −138.7, 109.3 | 0.67 (0.60–0.73) |
|                                     | Forehead | Prior to phototherapy (97) | 11.5 (−54.1 to 77.2) | −119.3, 109.3 | 0.75 (0.66–0.82) |
|                                     | Forehead | During or after phototherapy (137) | −25.9 (−112.1 to 60.2) | −138.6, 79.5 | 0.63 (0.54–0.71) |
|                                     | Sternum | Regardless of phototherapy (234) | −11.9 (−115.2 to 91.4) | −153.3, 113.3 | 0.56 (0.49–0.63) |
|                                     | Sternum | Prior to phototherapy (97) | 6.2 (−72.4 to 84.8) | −137.7, 113.3 | 0.70 (0.60–0.78) |
|                                     | Sternum | During or after phototherapy (137) | −34.5 (−143.8 to 74.8) | −153.3, 79.0 | 0.52 (0.43–0.60) |

*Shown are measures of agreement stratified by anatomical site of TcB assessment, gestational age at birth, and receipt of phototherapy. TcB, transcutaneous bilirubin; TSB, total serum bilirubin; LOA, limits of agreement. * Only 11 neonates born at 24–28 weeks’ gestation had the opportunity to have TSB or TcB measured before initiation of phototherapy, providing 12 paired TcB measurements. Accordingly, the related data are only presented for those infants receiving phototherapy.

Table 3. Test characteristics of TcB measurement at recommended TSB cut points

| Group assessed                      | Recommended TSB cut point, μmol/L | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV, % (95% CI) | NPV, % (95% CI) | Positive likelihood ratio (95% CI) | Negative likelihood ratio (95% CI) |
|-------------------------------------|-----------------------------------|-------------------------|-------------------------|----------------|----------------|-----------------------------------|-----------------------------------|
| Neonates born at 29–32 weeks’ gestation | >100                              | 73 (58–85)              | 73 (45–92)              | 90 (76–97)    | 46 (25–67)    | 2.7 (1.2–6.4)                     | 0.37 (0.21–0.64)                  |
| Neonates born at 33–35 weeks’ gestation | >170                              | 83 (64–94)              | 78 (66–87)              | 61 (45–77)    | 91 (81–97)    | 3.7 (2.3–6.0)                     | 0.22 (0.10–0.50)                  |

TcB, transcutaneous bilirubin; TSB, total serum bilirubin; PPV, positive predictive value; NPV, negative predictive value.
Fig. 2. Bland-Altman plot of paired forehead TcB and TSB measurements among neonates born at 24–28 weeks’ gestation (a), 29–32 weeks’ gestation (b), and 33–35 weeks’ gestation (c). TcB, transcutaneous bilirubin; TSB, total serum bilirubin.

(Figure continued on next page.)
Discussion

In this multisite, prospective cohort study of Canadian infants born preterm at 24\(^{0/7}\) to 35\(^{6/7}\) weeks’ gestation, TcB measured with the JM-105 at the forehead and sternum offered a reasonably accurate assessment of TSB, especially prior to starting phototherapy in preterm infants born between 33 and 35 weeks’ gestation. In preterm infants born at 33–35 weeks’ gestation, TcB demonstrated better agreement with TSB than among those born before 33 weeks’ gestation. Maternal ethnicity did not appreciably affect TcB.

As per our primary objective, we studied the agreement between TcB and TSB measurements among preterm infants using multiple TcB measurements per infant. Specifically, this study assessed the impact of phototherapy initiation, the anatomical site of measurement, gestational age at birth, and maternal ethnicity. This study used an adapted version of the Bland-Altman analysis, which accounts for repeated bilirubin measurements in the same infant [15, 16]. Previously, a regression analysis was employed to account for multiple measurements per infant [18]. The inclusion of a large number of repeated samples permitted a comprehensive analysis of TcB measurements within a diverse sample of neonates, surpassing the sample size from a previously completed study in India using the BiliChek [19].

Similar to previous studies of TcB among preterm infants, our study reported a mean TcB-TSB difference of ≤26 μmol/L [9, 18, 19]. After initiation of phototherapy and at a greater degree of prematurity, TcB-TSB agreement worsened. This is consistent with previous research that showed greater agreement between TcB and TSB prior to initiating phototherapy using the JM-103 and JM-105 devices [12, 20, 21]. As in prior studies, we saw no appreciable difference whether TcB was measured at the forehead or sternum prior to phototherapy [11, 14]; however, after the initiation of phototherapy, the current study suggests that the forehead may be the more preferred site for TcB measurement when using the JM-105 device. One reason for this may be the reduced exposure to phototherapy at the forehead from the eye mask used during treatment [22]. However, TSB measurements should be used to make clinical decisions, especially after the initiation of phototherapy. As with former studies [17, 23], ethnicity does not appear to appreciably affect the agreement between TcB and TSB measurements.

As a limitation, fewer TcB measurements were available before initiation of phototherapy than after, espe-
cially among infants born at 24–28 weeks’ gestation who started on phototherapy at a median of 26 h of age. The recruitment of extremely preterm infants was challenging in terms of obtaining parental consent prior to initiation of phototherapy. This study did not assess TcB-TSB agreement in relation to the time since phototherapy cessation and therefore did not differentiate between during or after phototherapy. Finally, as this study used the JM-105 device, the current findings may not be reflective of the performance of other TcB devices.

The clinical utility of TcB as a screening tool was also assessed at specific recommended treatment TSB thresholds in 2 preterm infant groups. Among infants born at 29–32 weeks, forehead TcB had an AUC of 0.76 to detect the recommended TSB threshold of >100 μmol/L. At this gestational age, a forehead TcB cut point of 85 μmol/L had the necessary sensitivity of 92% to detect the recommended TSB threshold of >100 μmol/L, even though the specificity was only 60%. In preterm infants at 33–35 weeks’ gestation, the corresponding AUC was 0.86 to detect the recommended TSB threshold of >170 μmol/L. Among these infants, a forehead TcB cut point of 156 μmol/L had the requisite sensitivity of 90%, with a slightly better specificity of 69% to detect the recommended TSB threshold of >170 μmol/L. Accordingly, TcB may be useful in screening for hyperbilirubinemia in low-risk preterm infants born at 33–35 weeks prior to the initiation of phototherapy. Among preterm infants born at 29–32 weeks’ gestation, TcB should be used more carefully as TSB approaches treatment thresholds. In all preterm infants, the recommended TSB thresholds of treatment need to be considered when deciding to use TcB in this population.

Clinicians should remain cognizant of the treatment thresholds for hyperbilirubinemia, based on gestational age at birth and other clinical factors for developing bilirubin toxicity [5]. Once an infant is on phototherapy, blood testing is often repeated regularly, to monitor the effect of phototherapy on bilirubin levels [12]. The tendency of TcB to underestimate TSB after the initiation of phototherapy in 84% of TcB measurements after the initiation of phototherapy seems problematic: relying on TcB alone might lead to improper discontinuation of phototherapy [12]. As such, TSB measurements should be used to make clinical decisions after the initiation of phototherapy, especially since most preterm infants start phototherapy after the first or second day of life. As a potential solution to the underperformance of TcB after initiation of phototherapy, for example, some small studies in term and preterm infants explored the effectiveness of measuring TcB on covered skin [20, 24]. A similar approach, with a larger sample size, should be considered in preterm infants, to determine the effectiveness of TcB after phototherapy.
In addition to procedural pain, repeated blood sampling in preterm infants can contribute to anemia [25]. Approximately 0.5 mL of blood sampling is required for TSB measurement in late-preterm infants. In the current study, each newborn received a mean of 7 TSB measurements, amounting to 3.5 mL of cumulative blood loss. The careful use of TcB as a screening tool may reduce blood sampling, especially in mid- and late-preterm infants.

**Conclusion**

Among preterm infants born at 33–35 weeks’ gestation, TcB with the JM-105 may offer a noninvasive, immediate approach to screening for hyperbilirubinemia prior to phototherapy. Careful use of TcB should be considered in infants born at <33 weeks’ gestation when TSB levels are approaching phototherapy thresholds. Its notable underestimation of TSB measurements after the initiation of phototherapy warrants limited use after the initiation of phototherapy and use of TSB measurements for clinical decision-making.

**Acknowledgment**

Some members of the Neonatal Hyperbilirubinemia Consortium: Rachael Allen, Jeffrey Antwi, Jillian Baker, Shangari Baleswaran, Matthew Barozzino, Tony Barozzino, Maria Casalino, Sohail Cheema, Mary Debono, Maria Ghobrial, Aadhiteya Jhaveri, Sharmilaa Kandasamy, Melissa Librach, Saisujani Rasiah, Sureka Selvakumaran, Heet Sheth, Ashvinie Sritharan, Geoffrey Travis, Jennifer Twiss, and Gayathri Visvanathaiyer.

**Statement of Ethics**

Institutional Research Ethics Board approval was obtained at all 3 participating sites, and informed written consent was provided by the parent(s) (St. Michael’s Hospital REB reference #15-376).

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

This study was funded by Drager Medical Systems Inc., Germany, and the University of Toronto Open Fellowship Award, Toronto, Canada.

**Author Contributions**

Thivia Jegathesan, Dr. Joel Ray, and Dr. Michael Sgro* conceptualized the design of the study, drafted the initial manuscript, and reviewed and revised the manuscript. Dr. Howard Berger and Dr. Robin Hayeems assisted in the design of the study, assisted with the analyses, and critically reviewed and revised the manuscript. Dr. Vibhuti Shah and Dr. Douglas Campbell assisted in the design of the study, coordinated and supervised data collection, and reviewed and revised the manuscript.

**Study Registration**

This study is registered on https://clinicaltrials.gov/ct2/show/NCT02774434.

**References**

1 American Academy of Pediatrics. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297–316.
2 Barrington K, Sankaran K; Canadian Pediatric Society. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks’ gestation) – summary. J Paediatr Child Health. 2007;12(5):401–18.
3 Sgro M, Kandasamy S, Shah V, Ofner M, Campbell D. Severe neonatal hyperbilirubinemia decreased after the 2007 canadian guidelines. J Pediatr. 2016;171:43–7.
4 Bhutani VK, Wong RJ. Bilirubin neurotoxicity in preterm infants: risk and prevention. J Clin Neonatol. 2013;2(2):61–9.
5 Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol. 2012;32(9):660–4.
6 Hussain AS, Shah MH, Lakhdir M, Ariff S, Demas S, Qaiser F, et al. Effectiveness of transcutaneous bilirubin measurement in managing neonatal jaundice in postnatal ward of a tertiary care hospital in Pakistan. BMJ Paediatr Open. 2017;1(1):e000065.
7 Jnah A, Newberry DM, Eisenbeisz E. Comparison of transcutaneous and serum bilirubin measurements in neonates 30 to 34 weeks’ gestation before, during, and after phototherapy. Adv Neonatal Care. 2018;18(2):144–53.
8 Raba AA, O’Sullivan A, Miletin J. Transcutaneous bilirubinometry during and after phototherapy in preterm infants: a prospective observational study. BMJ Paediatr Open. 2020;4(1):e000681.
9 Rohsiswatno R, Onewari H, Amandito R, Stakti HA, Windiaustutti E, Roeslani RD, et al. Agreement test of transcutaneous bilirubin and bilistick with serum bilirubin in preterm infants receiving phototherapy. BMC Pediatr. 2018;18(1):315.
10 Brummelte S, Grunau RE, Chau V, Posskt KK, Brant R, Vinall J, et al. Procedural pain and brain development in premature newborns. Ann Neurol. 2012;71(3):385–96.
Transcutaneous Bilirubin Measurements in Preterm Infants

Agrawal G, Garg K, Sitaraman S, Sarna A. Comparison of diagnostic accuracy of different sites for transcutaneous bilirubin measurement in early preterm infants. Indian J Pediatr. 2019;86(1):32–7.

Hulzebos CV, Vader-van Imhoff DE, Bos AF, Dijk PH. Should transcutaneous bilirubin be measured in preterm infants receiving phototherapy? The relationship between transcutaneous and total serum bilirubin in preterm infants with and without phototherapy. PloS one. 2019;14(6):e0218131.

Hynes S, Moore Z, Patton D, O’Connor T, Nugent L. Accuracy of transcutaneous bilirubin versus serum bilirubin measurement in preterm infants receiving phototherapy: a systematic review. Adv Neonatal Care. 2020; 20(6):E118–26.

Nagar G, Vandermeer B, Campbell S, Kumar M. Reliability of transcutaneous bilirubin devices in preterm infants: a systematic review. Pediatrics. 2013;132(5):871–81.

Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat. 2007;17(4):571–82.

Zou GY. Confidence interval estimation for the Bland-Altman limits of agreement with multiple observations per individual. Stat Methods Med Res. 2013;22(6):630–42.

Afanetti M, Eleni Dit Trolli S, Yousef N, Jrad I, Mokhtari M. Transcutaneous bilirubinometry is not influenced by term or skin color in neonates. Early Hum Dev. 2014;90(8):417–20.

Maisels MJ, Coffey MP, Kring E. Transcutaneous bilirubin levels in newborns. J Perinatol. 2015;35(9):739–44.

Chawla D, Jain S, Kaur G, Sinhmar V, Guglani V. Accuracy of transcutaneous bilirubin measurement in preterm low-birth-weight neonates. Eur J Pediatr. 2014;173(2):173–9.

Costa-Posada U, Concheiro-Guisan A, Taboas-Ledo MF, Gonzalez-Colmenero E, Gonzalez-Duran ML, Suarez-Albo M, et al. Accuracy of transcutaneous bilirubin on covered skin in preterm and term newborns receiving phototherapy using a JM-105 bilirubinometer. J Perinatol. 2019;40:226–31.

Ahmed M, Mostafa S, Fisher G, Reynolds TM. Comparison between transcutaneous bilirubinometry and total serum bilirubin measurements in preterm infants. Ann Clin Biochem. 2010;47(Pt 1):72–7.

De Luca D, Dell’Orto V. Patched skin bilirubin assay to monitor neonates born extremely preterm undergoing phototherapy. J Pediatr. 2017;188:122–7.

Counsilman CE, Heeger LE, Tan R, Bekker V, Zwaginja JJ, te Pas AB, et al. Iatrogenic blood loss in extreme preterm infants due to frequent laboratory tests and procedures. J Matern Fetal Neonatal Med. 2019:1–6.